David R. Jones

2 ta ish

Memorial Sloan Kettering Cancer Center

1. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

   Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière +27

   MaqolaOAOchiq kirish20213 iqtibos

   ABIABI:AkademIndex/2026.other.102892

2. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

   Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas +5

   MaqolaOAOchiq kirish20162 iqtibos

   ABIABI:AkademIndex/2026.other.020461